Notice2022-10941

Advisory Committee; Gastrointestinal Drugs Advisory Committee; Renewal; Correction

Primary source

Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.

Published
May 23, 2022

Issuing agencies

Health and Human Services DepartmentFood and Drug Administration

Abstract

The Food and Drug Administration (FDA) is correcting a notice entitled "Advisory Committee; Gastrointestinal Drugs Advisory Committee; Renewal" that appeared in the Federal Register of May 11, 2022. The document announced the renewal of the Gastrointestinal Drugs Advisory Committee. The document was published with the incorrect docket number. This document corrects that error.

Full Text

<html>
<head>
<title>Federal Register, Volume 87 Issue 99 (Monday, May 23, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 99 (Monday, May 23, 2022)]
[Notices]
[Page 31245]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-10941]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2022-N-0619]


Advisory Committee; Gastrointestinal Drugs Advisory Committee; 
Renewal; Correction

AGENCY: Food and Drug Administration, HHS

ACTION: Notice; correction.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is correcting a notice 
entitled ``Advisory Committee; Gastrointestinal Drugs Advisory 
Committee; Renewal'' that appeared in the Federal Register of May 11, 
2022. The document announced the renewal of the Gastrointestinal Drugs 
Advisory Committee. The document was published with the incorrect 
docket number. This document corrects that error.

FOR FURTHER INFORMATION CONTACT: Rhea Bhatt, Division of Advisory 
Committee and Consultant Management, Center for Drug Evaluation and 
Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 
31, Rm. 2434, Silver Spring, MD 20993-0002, 301-796-9001, email: 
<a href="/cdn-cgi/l/email-protection#efa8a6abaeacaf898b8ec187879cc1888099"><span class="__cf_email__" data-cfemail="4f08060b0e0c0f292b2e6127273c61282039">[email&#160;protected]</span></a>.

SUPPLEMENTARY INFORMATION: In the Federal Register of Wednesday, May 
11, 2022 (87 FR 28834), in FR Doc. 2022-10040, on page 28834, the 
following correction is made:
    1. On page 28834, in the first column of the header of the 
document, ``Docket No. FDA-2021-N-0619'' is corrected to read ``Docket 
No. FDA-2022-N-0619''.

    Dated: May 13, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022-10941 Filed 5-20-22; 8:45 am]
BILLING CODE 4164-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
Indexed from Federal Register on May 23, 2022.

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.